Hosta

by | Mar 16, 2018 | Hosta

How Can We Help?
You are here:
< Back

Glycerol phenylbutyrate, sold under the brand name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body.[3] It is an FDA-approved prescription drug in the US.[4] It was developed by Hyperion Therapeutics based on the existing medication sodium phenylbutyrate, and received approval in February 2013.[5]

Society and culture

Economics

Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales).[6]

References

  1. ^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
  2. ^ "Ravicti- glycerol phenylbutyrate liquid". DailyMed. 13 September 2021. Archived from the original on 3 May 2023. Retrieved 4 July 2023.
  3. ^ "FDA approves new drug for the chronic management of some urea cycle disorders" (Press release). U.S. Food and Drug Administration. 1 February 2013. Archived from the original on 2013-03-07. Retrieved 2013-04-01.
  4. ^ "FDA Approved Drug Products: Ravicti". Drugs@FDA. U.S. Food and Drug Administration. Archived from the original on 29 June 2017. Retrieved 18 February 2018.
  5. ^ Herder M (April 2016). "Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada". Journal of Law and the Biosciences. 3 (1): 158–166. doi:10.1093/jlb/lsv060. PMC 5033429. PMID 27774236.
  6. ^ "Horizon Pharma to Acquire Hyperion Therapeutics for $1.1B". Genetic Engineering & Biotechnology News. 30 March 2015. Archived from the original on 26 August 2017. Retrieved 18 February 2018.


Categories
Table of Contents